References
- Ortega-Ruiz M, Soria-Chacartegui P, Villapalos-García G, Abad-Santos F, Zubiaur P. The Pharmacogenetics of Treatment with Quetiapine. Future Pharmacology [Internet]. 2022; 2(3):[276-86 pp.].
- Mauri MC, Paletta S, Di Pace C, Reggiori A, Cirnigliaro G, Valli I, et al. Clinical Pharmacokinetics of Atypical Antipsychotics: An Update. Clinical Pharmacokinetics. 2018;57(12):1493-528.
- Spina E, Pisani F, de Leon J. Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. Pharmacol Res. 2016;106:72-86.
- Le Daré B, Ferron P-J, Allard P-M, Clément B, Morel I, Gicquel T. New insights into quetiapine metabolism using molecular networking. Scientific Reports. 2020;10(1):19921.
- Lee J, Beers JL, Geffert RM, Jackson KD. A Review of CYP-Mediated Drug Interactions: Mechanisms and In Vitro Drug-Drug Interaction Assessment. Biomolecules [Internet]. 2024; 14(1).
- López-Muñoz F, Alamo C. Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders. Front Psychiatry. 2013;4:102.
- Beydoun A, DuPont S, Zhou D, Matta M, Nagire V, Lagae L. Current role of carbamazepine and oxcarbazepine in the management of epilepsy. Seizure - European Journal of Epilepsy. 2020;83:251-63.
- Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord. 2014;16(4):409-31.
- May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet. 2003;42(12):1023-42.
- Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet. 2013;52(11):927-66.
- de Leon J, Spina E. Possible Pharmacodynamic and Pharmacokinetic Drug-Drug Interactions That Are Likely to Be Clinically Relevant and/or Frequent in Bipolar Disorder. Curr Psychiatry Rep. 2018;20(3):17.
- Andreasen AH, Brøsen K, Damkier P. A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4. Epilepsia. 2007;48(3):490-6.
- Zhang C, Zuo Z, Kwan P, Baum L. In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia. 2011;52(10):1894-904.
- Boulton DW, DeVane CL, Liston HL, Markowitz JS. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002;71(2):163-9.
- Kim DW, Weon KY, Hong EP, Chung EK, Lee KT. Comparative Physicochemical and Pharmacokinetic Properties of Quetiapine and Its Active Metabolite Norquetiapine. Chem Pharm Bull (Tokyo). 2016;64(11):1546-54.
- Saiz-Rodríguez M, Belmonte C, Román M, Ochoa D, Jiang-Zheng C, Koller D, et al. Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants. Basic Clin Pharmacol Toxicol. 2018;123(4):474-85.
- Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018;51(1-02):9-62.
- Adachi N, Ito M. Epilepsy in patients with schizophrenia: Pathophysiology and basic treatments. Epilepsy & Behavior. 2022;127:108520.
- Indorf P, Patzak A, Lichtenberger FB. Drug metabolism in animal models and humans: Translational aspects and chances for individual therapy. Acta Physiologica 2021, 233, e13734.
- Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 2016, 7, 27-31.
- Ciocotișan IM, Muntean DM, Vlase L. Bupropion Increased More than Five Times the Systemic Exposure to Aripiprazole: An In Vivo Study in Wistar albino Rats. Metabolites [Internet]. 2024; 14(11).
- de Leon J. The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: A summary of the current state for clinicians. Revista de Psiquiatría y Salud Mental (English Edition). 2015;8(2):97-115.
- Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol. 2006;61(1):58-69.
- Nickl-Jockschat T, Paulzen M, Schneider F, Grözinger M. Drug Interaction Can Lead to Undetectable Serum Concentrations of Quetiapine in the Presence of Carbamazepine. Clinical Neuropharmacology. 2009;32(1).
- Wong YW, Yeh C, Thyrum PT. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. J Clin Psychopharmacol. 2001;21(1):89-93.
- McGrane IR, Loveland JG, Zaluski HJ, Foster KD. Serum Quetiapine Concentration Changes with Concomitant Oxcarbazepine Therapy in a Boy with Autism Spectrum Disorder. J Child Adolesc Psychopharmacol. 2015;25(9):729-30.
- Sun Z, Zhang Z, Ji M, Yang H, Cromie M, Gu J, et al. BDE47 induces rat CYP3A1 by targeting the transcriptional regulation of miR-23b. Scientific Reports. 2016;6(1):31958.
- Hammer H, Schmidt F, Marx-Stoelting P, Pötz O, Braeuning A. Cross-species analysis of hepatic cytochrome P450 and transport protein expression. Arch Toxicol. 2021;95(1):117-33.